{"name":"GI Innovation, Inc.","slug":"gi-innovation-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"trastuzumab deruxtecan (T-DXd)","genericName":"trastuzumab deruxtecan (T-DXd)","slug":"trastuzumab-deruxtecan-t-dxd","indication":"Locally advanced or metastatic HER2-positive breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"trastuzumab deruxtecan (T-DXd)","genericName":"trastuzumab deruxtecan (T-DXd)","slug":"trastuzumab-deruxtecan-t-dxd","phase":"phase_3","mechanism":"Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.","indications":["Locally advanced or metastatic HER2-positive breast cancer","Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUW9SSkhlUV8zekRBN0JwRU5MRG5YSXhENlUwSXhsYTdPRTAzSnJ5RS1KYXp1RzVrMjAtZ2p5WThuTDh1V2ZZT3FwTFlLYkw2dnZrNGlwU05GWDBseDdSM0NPU0plaGpja2RieGhPVlJWQ0xrSExpZkVzQ0RtM0lrY0dxMXliV2JaRjU3TXhzVmRPRk1lRHpF?oc=5","date":"2026-04-08","type":"regulatory","source":"openPR.com","summary":"Food Allergy Pipeline 2026: Latest FDA Approvals, Clinical - openPR.com","headline":"Food Allergy Pipeline 2026: Latest FDA Approvals, Clinical","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNWhFN2xjanY2Wmg3M0JHZHhyNTFScnhWUHV0M1pfRHNXc3BxMmMyM0JSUjFkTWhDdHE3NDhXVUlleEdmOF9MbWVOT3g1T1VzSmlxZEYyX1ZUd0hYRUdiSGRKcXc2UEEwWEtya2d1LXJyd2RUMllwRlVGUDVXekZQUFNzWEZ4N2xXcmszUHBrUS13R3dIeExmN09Qb2tnQ0hDY1RUeEtOUnRtVDRVeVpNenNIdnBReEtEbzUwZUNDdENoUzRDRlhvZ1NHc1NMb3otLUViOFJBZDlHQnpHVm15MGIwUjIwQkwwMFM5Z19ra05KLTBT?oc=5","date":"2026-03-19","type":"pipeline","source":"PR Newswire","summary":"GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer - PR Newswire","headline":"GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9LeVdBQnFoY1ZGcmxoS2xzdVRsQUhzOVl3X3RZUDJBdEV4LUx1Zy1BZ19PRHptRThhandqRlJXemxrSG9nTFJvb0M0eWdDVlZ4YlNyVnlBNDU0a0x4VEoyVmNjZG5IYlNLeWVNUNIBcEFVX3lxTE5tSGllVkVJS3YxeEJXZlp3bDBMTk90UXBqTkNSbHZDaFF3WkZlbm9EQlhpVlVORGI4TVlIbUtwZGZGcXFwb2MybkI2WVItUEVqNVpKaTY0M0dUeE5pbHdET2dZaTNpM3dCRU5abHRMRDg?oc=5","date":"2026-03-03","type":"pipeline","source":"thebionews.net","summary":"GI Innovation launches ‘K-Bio Innovation’ initiative as the KRW 45 trillion Keytruda ecosystem takes center stage - thebionews.net","headline":"GI Innovation launches ‘K-Bio Innovation’ initiative as the KRW 45 trillion Keytruda ecosystem takes center stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE16ZVZfS0NkMzB6TlpFRWc4enFvc2NLRnltQ3RoZU5CUlMzLWc2UjJldHlxQUxuNmxlTU4tckQ2SXdWN1Bub3RzT2VKQ2JfbUJTV1BjbVVrQkpWVHg4R2FSbV9uM0dKdWFsRFlnY1FEd0tQT0FEUnlscnFrMGtzdw?oc=5","date":"2025-12-22","type":"pipeline","source":"Global Growth Insights","summary":"What Are the Top 20 Gastroenterology Companies in 2025? - Global Growth Insights","headline":"What Are the Top 20 Gastroenterology Companies in 2025?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNkJCTmRYQ2d5Wmh6ZlViN0dNS09mZVc0UkdPd09uVkxwbFVWeWJRM1pIcGc4TFNNeGpZMmE2T19Jdk5rcTdHMHp6aUdLanM4c2p0WG5ZNmpkZlZWcXN0dnVGYXRhaVJFaDFOdmVCTm1RZEY0NXVFeXQ2MlllSEVlWTFwTzhVWXJIdGhz?oc=5","date":"2025-11-07","type":"pipeline","source":"Fortune Business Insights","summary":"Gastrointestinal Therapeutics Market Size, Share | Growth [2034] - Fortune Business Insights","headline":"Gastrointestinal Therapeutics Market Size, Share | Growth [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNaFFuMzExaUNiNzhZRzRwSHhPRjMyWTNIbUp3RUtYV1R5Rzc0emY0MlE4SlY3a2lZYzQ0ZkZrREhxcEJQb3I4TWUtVXlwdGtpS2RfNjJwSXJPbUJvXzZCSHhvdHU1c1AzYkhGbXBIWnVyNURlb3dKN0xaYWNMcGxmSzlGalFhWGtuWVRSNTZaUDRfT0V5bHlFMXdmR3FLYzcyOHA1ag?oc=5","date":"2025-10-28","type":"pipeline","source":"BioWorld News","summary":"Opportunity, risks of cell therapy to tackle aging and disease - BioWorld News","headline":"Opportunity, risks of cell therapy to tackle aging and disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9vRmJsZ1NIQ2dWRGJZQ0JNakc2ckxpYjVod2x3RXNIN1Q3Y3c0Q0VrSVdGR0tQd2VXbzlScm9yeXd6Vl9DR1duZjNZTkRvWTNtSXlldmVrbmY3SHhuMEFLNjAzNWRGckhWaUwtZWpUWlM2cVFlUUpiWkNqTDg?oc=5","date":"2025-10-15","type":"pipeline","source":"BioCentury","summary":"Pruzanski named CEO of Alentis - BioCentury","headline":"Pruzanski named CEO of Alentis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9EUXl1NS1wTEg2NnFWUFJBWFRPbXJLV0hGSkR3TklGY0I2WEJBa1hiZ3JaejluekpySmEtNGs3SXFEMFhvREVtT25PeWY4eTdrM1B3Y2xaMS02bl9WWGp2WUl6MUNXVUlzSk16QjhR0gFyQVVfeXFMT3oxRXlaWndhUkRJVTNMUUh5Vk9hSjlKVGEteWJ3cFZpOE40UzJZdU9DenlzTmZkWGR5WFZ0VndNNmc1WklMaW5SYTNQT3U3UnlaSTRwOGhjR3BfTDBmYlhndzNUTDNaNjVRX3N5UVB3MUlR?oc=5","date":"2025-09-12","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan R&D chief steps down, leaving gap after Leclaza success - koreabiomed.com","headline":"Yuhan R&D chief steps down, leaving gap after Leclaza success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9rUnFTdVBQMUVMMzBHNk5UWjdyUGg4VHZ2T1B5cjhnV19hOTZpSnFjdEVGQ0tueVZTVlFyS2ItdzhKd3pkVkpKV1VhQXg5cXRKR1N6cVpUSkF2ZldNVEswOWJTQ0FLLXRLX1hZaG130gFyQVVfeXFMTTROU29vVXdteWJIRHMxSV9LUlZ3Z2dKdUdNZy1aNTdzY1Y3YlZPWVZEUW80RGdFQWJGR1YwcmY4SmFHR1dEZjZQbk1qQm1sMkhFcXhmNk5VclIzd3RmQldqUWVNOU9wWnFJUTBhWG4xRnBB?oc=5","date":"2025-08-11","type":"pipeline","source":"koreabiomed.com","summary":"GI Biome changes name to GI Longevity to focus on the anti-aging market - koreabiomed.com","headline":"GI Biome changes name to GI Longevity to focus on the anti-aging market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQQ0cxTGN4WWZYWlRvRjZSeFBrdDVJcDZqYUcySkM0UHBCcTBLVXlpQ3J5d1lJTmlnUW5FUkFwN3R4VEh5QmRfaFpyWW9Hdm1zcmZGRWx6clZmWFk0bUM2dzlxWkZqaDJxX1hJSVVkWGd2UjkwVVRaRXE1MzlhSVZOctIBlAFBVV95cUxNVldfckZXOFlBNFpPdF9uVmJsZTBCYTFLSHotME5pT1ZqYUU2Y2NqeGI1RmR2WlRqLVl4TlVEY3JQT0RQN2hDaldNRjZfdDh5aDlMcWltWVk1a0VRQ2IwZWF1SnVRNlh5QkFGOGt2eU9xY0lITWZpaGliY3lRb3dBN1c3dmFrN3BVWFBBaFpBTWItQ3Ex?oc=5","date":"2025-06-16","type":"pipeline","source":"Chosunbiz","summary":"Korean biotech firms pursue global opportunities at BioUSA 2025 in Boston - CHOSUNBIZ - Chosunbiz","headline":"Korean biotech firms pursue global opportunities at BioUSA 2025 in Boston - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXcEluZWczNmx3SmxLY0ZwTXo2MFBjVlgxcktGYUg4U2VueGRSRU9fREs1Q3J0dVY2SkNaY3hkTV9IZ1NYczVLRGhOWVk2TTEtMmoybktHREFuRkZ0dVlyOFQxdEVra3RZTHpIVkZR?oc=5","date":"2025-05-16","type":"deal","source":"KED Global","summary":"South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly - KED Global","headline":"South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcXdCbkstZGxTQmVxeGhMcEhQZDJCWGpscjIxOVpodERHcWJxSGdVT0Nabm1zTGVwejhWZU5Cb1lKX25FZjRPNUtxRHNQMTVXTEZ0S284VThPbEtpTjBHcVhvai03U19lZlF1dEtOSTVxSmZWN3V4dkw0NFZZTnVraXlqcG5LcmFpZWJ2UXEyTXdSd2ZvMXBBZUtNUVYtS2llV3FUQU9RdTVRWlRZZXpxMWhsajB3RmtDbWNmdXdRVU9RS3VKUC16OVVfY3ctWklrdFVXVE1FUV81Vl8yMVNfSTFJanNySWJFMDRRMjJTX3paOFBRQncyTg?oc=5","date":"2022-03-04","type":"pipeline","source":"businesswire.com","summary":"GI Innovation Recruits Chief Executive Officer Byung-Geon Rhee Former CEO of GC Pharma, SCM Lifescience Corp. - businesswire.com","headline":"GI Innovation Recruits Chief Executive Officer Byung-Geon Rhee Former CEO of GC Pharma, SCM Lifescience Corp.","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}